老年晚期非小细胞肺癌患者的免疫治疗效果观察

Observation of immunotherapy efficacy on elderly patients with advanced non-small cell lung cancer

目的 探讨免疫检查点抑制剂(ICIS)在老年非小细胞肺癌(NSCLC)患者免疫治疗中的效果及安全性。方法 选取具有完整随访资料在菏泽市牡丹人民医院2020年1月至2022年7月就诊治疗的NSCLC患者50例,按年龄分为观察组(年龄≥65岁)28例、对照组(年龄<65岁)22例,两组均给予程序性死亡蛋白-1(PD-1)抑制剂单抗治疗,随访半年以上,比较两组疗效、药物不良反应、生存曲线。结果 两组患者PD-1抑制剂单抗治疗疗效比较,差异无统计学意义(P> 0.05)。治疗期间两组不良反应发生例数比较,差异无统计学意义(P> 0.05)。结论 采用PD-1抑制剂单抗的ICIS治疗在65岁及以上NSCLC患者中获得了较好的效果和安全性,且与年轻患者相近。

Objective To investigate the efficacy and safety of immune checkpoint inhibitors(ICIS)in immunotherapy on elderly patients with non-small cell lung cancer(NSCLC).Methods A total of 50 patients with NSCLC admitted to and treated in Mudan People’s Hospital in Heze City from January 2020 to July 2022 with complete follow-up data available were selected and divided into the observation group(n=28,age≥65 years)and the control group(n=22,age<65 years)according to their ages.Both groups were treated with programmed death protein-1(PD-1)inhibitor monoclonal antibody,and were followed up for more than half a year.The efficacy,adverse drug reactions(ADRs),and survival curves were compared between two groups.Results There was no statistically significant difference in the therapeutic efficacy of PD-1 inhibitor monoclonal antibody of patients between the two groups(P>0.05).There was no statistically significant difference in the number of cases of ADRs between the two groups during treatment(P>0.05).Conclusion The use of PD-1 inhibitor monoclonal antibodies for ICIS has achieved relatively good efficacy and safety in patients with NSCLC aged 65 and above,with similar efficacy and safety in young patients.